"The pill" goes natural with potential new bestseller

Teva has announced the EU approval of NOMAC/E2, the first monophasic contraceptive with natural estrogen. The perceived increased safety of natural estrogen and a global launch will drive sales of the product, making it a leading hormonal contraceptive brand. To maximize its potential, however, Teva needs to show improved safety over synthetic estrogen contraceptives in post-marketing studies.

Published By Datamonitor

$18 million in funding for center for deadly diseases

A National Institutes of Health body has set aside funding worth $18 million to establish a computer database designed to identify and exploit the weak spots in a number of deadly microorganisms.

Published By MarketLine

3M and VaxInnate partner to develop flu vaccine patch

3M Drug Delivery Systems, a developer of transdermal drug delivery technology, has signed a non-exclusive licensing agreement with VaxInnate, a biotechnology company, to develop a flu vaccine patch for use against a pandemic flu outbreak.

Published By MarketLine

3M Drug Delivery expands pMDI manufacturing capability

3M Drug Delivery Systems, a developer of pharmaceuticals using inhalation or transdermal drug delivery technology, has announced the expansion of the pressurized metered dose inhaler, or pMDI, fill line at its facility in Northridge, California, extending the company's manufacturing capability.

Published By MarketLine

3M Drug Delivery Systems and Purdue Pharma to develop seven day analgesic

Published By MarketLine

3M Drug Delivery Systems launches new Microchannel Skin System

3M Drug Delivery Systems has launched the 3M Microchannel Skin System, a new tool used for pretreatment of patients' skin prior to dermatological applications and procedures.

Published By MarketLine

3M Drug Delivery Systems licenses vaccine adjuvants to VaxInnate

3M Drug Delivery Systems has signed an agreement with VaxInnate under which VaxInnate acquires the use of 3M's patented toll-like receptor, or TLR, agonists for use as vaccine adjuvants.

Published By MarketLine

3M licenses Cambridge Consultants's dry powder inhaler technology

3M, a diversified technology company, has announced that its drug delivery systems division has signed an exclusive technology licensing and purchase agreement with Cambridge Consultants for its Conix dry powder inhaler technology platform.

Published By MarketLine

3M Pharmaceuticals granted FDA approval for Aldara

3M has confirmed that the FDA has approved its Aldara product, the first prescription therapy in nearly a decade for the treatment of superficial basal cell carcinoma, a type of nonmelanoma skin cancer.

Published By MarketLine

3M Reports Third-Quarter, Nine-Month Results

3M has reported sales and earnings for the third quarter and first nine months of 2001. Third-quarter net income - excluding non-recurring items - totaled $437 million, or $1.10 per share, down 12 percent from $499 million, or $1.25 per share, in the same quarter of 2000. Currency effects reduced earnings for the quarter by 6 cents per share, or 5 percent.

Published By MarketLine